肿瘤免疫治疗后超进展现象的研究进展

Research Progress of Hyperprogression after Tumor Immunotherapy

抗细胞毒性T淋巴细胞抗原4(CTLA-4)抗体和免疫检查点抑制剂对各种癌症患者有独特的疗效。然而,免疫检查点抑制剂单一疗法的低应答率和超进展(HP)疾病的发生限制了免疫检查点抑制剂的临床应用。HP是一种新的进展模式,肿瘤体积增长和疾病进展出乎意料的迅速,患者生存期明显缩短。鉴于HP常有不良临床结局出现,因此迫切需要有效的生物标志物来预测HP的发生。本文就HP的判别标准、预测相关生物标记物、“假性进展”和“HP”现象鉴别作一综述。

Anti-cytotoxic T-lymphocyte antigen 4(CTLA-4)antibodies and immune checkpoint inhibitors(ICIs)have unique efficacy in patients with a variety of cancers.However,the low response rate to immune checkpoint inhibitor monotherapy and the occurrence of hyperprogression(HP)have limited the clinical use of immune checkpoint inhibitors.HP is a new progression pattern with unexpectedly rapid tumor volume growth and disease progression,which significantly shorten patient’s survival.Given that the phenomenon of HP is often associated with adverse clinical outcomes,there is an urgent need for effective biomarkers to predict the occurrence of HP.In this paper,we review the current criteria for identifying HP,the biomarkers associated with HP prediction,and the identification of“pseudoprogression”and“HP”phenomena.